Add BrightSurf on Google Email

VHIO-led study unveils predictive biomarker of response to therapy in patients with microsatellite stable BRAFV600E metastatic colorectal cancer

A new predictive biomarker, RNF43 mutations, has been identified as a significant predictor of response to anti-BRAF/EGFR combinatory therapy in patients with microsatellite stable BRAF V600E metastatic colorectal cancer. This biomarker is associated with improved progression-free and overall survival rates.

SourceVall d'Hebron Institute of Oncology·JournalNature Medicine·DateSep 27, 2022

Colonoscopies in FIT-positive persons requires much higher ADR than primary colonoscopy

A cohort study found that endoscopists performing colonoscopies in FIT-based screening programs should aim for markedly higher ADRs compared to primary colonoscopy screening. The study suggests that high ADRs are associated with lower colorectal cancer incidence and mortality. Researchers recommend using ADR targets, including differen...

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeObservational study·DateSep 26, 2022

Journal editorial: Regenstrief researcher calls for tailoring colorectal cancer screening for 45-to-49-year-olds

The author suggests that individuals at average risk between 45 and 49 years old should consider non-invasive screening alternatives, such as fecal immunochemical tests or stool DNA testing. This approach would benefit others who need more invasive screening resources and reduce the strain on colonoscopy services.

SourceRegenstrief Institute·JournalClinical Gastroenterology and Hepatology·DateSep 22, 2022

New UCI-led research reveals the circadian clock influences cell growth, metabolism and tumor progression

A new UCI-led study reveals that the circadian clock's disruption can drive colorectal cancer progression through genetic mutations and increased tumor growth. The study found that both environmental and genetic disruptions of the circadian clock contribute to APC loss of heterozygosity, a critical factor in CRC development.

SourceUniversity of California - Irvine·JournalScience Advances·DateAug 10, 2022

Clinical trial reveals strategy for increasing shared decision-making by physicians and older patients about colorectal cancer screening

A recent clinical trial led by Massachusetts General Hospital validated a strategy for increasing shared decision-making about colorectal cancer screening in older patients. Brief physician training plus reminders resulted in patients reporting higher quality conversations, with more discussing their preferences and having more options...

SourceMassachusetts General Hospital·JournalJournal of General Internal Medicine·TypeExperimental study·DateAug 5, 2022

Oncotarget | Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

Researchers investigated the effects of neoadjuvant chemoradiotherapy on CD8+ tumor-infiltrating lymphocytes, PD-L1, and mucin expression in rectal cancer patients. The study found that nCRT exposure was associated with higher mucin expression and a non-significant difference in PD-L1 expression, suggesting an immunosuppressive phenotype.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateAug 2, 2022

New AI model for the accurate diagnosis of neoplasia associated with inflammatory bowel disease

Researchers developed an AI system that classifies IBDN lesions accurately, displaying image-based diagnostic ability with 64.5% sensitivity and 89.5% specificity. The correct diagnosis rate of the AI system was 79.0, surpassing that of endoscopists, who achieved a 77.8% accuracy rate.

SourceOkayama University·JournalJournal of Gastroenterology and Hepatology·TypeComputational simulation/modeling·DateJul 13, 2022

New classification system proposed for colorectal cancer to guide treatment and clinical trials

A new classification system for colorectal cancer has been proposed, grouping cancers into five subtypes based on epithelial status, microsatellite status, and fibrosis. This update could inform targeted drug development efforts and improve treatment approaches for patients with different biological characteristics.

SourceSingHealth·JournalNature Genetics·TypeRandomized controlled/clinical trial·DateJul 1, 2022

Eligible younger U.S. adults less likely to meet recommended colorectal cancer screening guidelines and face greater disparities

A study found that younger U.S. adults are less likely to be screened for colorectal cancer despite being eligible under new guidelines, with greater disparities observed across race, ethnicity, income, education, and insurance coverage. Screening participation increased over time but was smallest among individuals age 50-54.

SourceUniversity of Texas Health Science Center at Houston·JournalCancer Epidemiology Biomarkers & Prevention·DateJun 29, 2022

Eligible younger Americans less likely to meet recommended colorectal cancer screening guidelines and face greater disparities

Researchers found eligible younger Americans (45-54) are less likely to meet recommended colorectal cancer screening guidelines due to work, family, insurance, and healthcare barriers. These disparities may worsen as the age group is expanded under new USPSTF recommendations.

SourceAmerican Association for Cancer Research·JournalCancer Epidemiology Biomarkers & Prevention·DateJun 29, 2022

Microbial link between Western-style diet and incidence of colorectal cancer uncovered

Researchers analyzed data from over 134,000 participants and found a strong association between Western diets and colorectal tumors containing the pks+ E. coli bacteria. The study suggests that specific components of Western-style diets may increase the risk of colorectal cancer by promoting the growth of these pathogenic bacteria.

SourceBrigham and Women's Hospital·JournalGastroenterology·TypeObservational study·DateJun 27, 2022

AGA releases evidence-based principles to guide creation of national colorectal cancer screening approach

The American Gastroenterological Association has released a series of evidence-based position statements guiding the creation of a national colorectal cancer screening approach. The goal is to eliminate barriers and reduce mortality by ensuring equitable access to CRC screening programs for all individuals.

SourceAmerican Gastroenterological Association·JournalGastroenterology·DateJun 14, 2022

Sanoff offers perspective on a promising rectal cancer study in the New England Journal of Medicine

A recent study published in the New England Journal of Medicine found that dostarlimab was effective in treating a subtype of rectal cancer, showing remarkable responses and resolving difficult symptoms. The treatment offers a more effective and less toxic alternative to traditional chemotherapy and radiation.

SourceUNC Lineberger Comprehensive Cancer Center·JournalNew England Journal of Medicine·TypeCommentary/editorial·DateJun 5, 2022

“Keto” molecule may be useful in preventing and treating colorectal cancer, Penn study suggests

Researchers found that a molecule called beta-hydroxybutyrate (BHB) produced in the liver during low-carb diets can suppress colorectal tumor growth. BHB's anti-tumor effects were replicated by giving mice the molecule directly, indicating its potential as a preventive and treatment for colorectal cancer.

SourceUniversity of Pennsylvania School of Medicine·JournalNature·TypeExperimental study·DateApr 27, 2022

HIV drug stabilizes disease progression in metastatic colorectal cancer

A clinical trial reveals that lamivudine, a widely used HIV treatment, halted disease progression in 28% of patients with fourth-line metastatic colorectal cancer. The study suggests an unexpected promising direction for cancer treatment and encourages the exploration of pairing reverse transcriptase inhibitor therapy with immunotherapy.

SourceMassachusetts General Hospital·JournalCancer Discovery·TypeRandomized controlled/clinical trial·DateApr 5, 2022